231 related articles for article (PubMed ID: 22923450)
1. Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP.
Yin S; Kaluz S; Devi NS; Jabbar AA; de Noronha RG; Mun J; Zhang Z; Boreddy PR; Wang W; Wang Z; Abbruscato T; Chen Z; Olson JJ; Zhang R; Goodman MM; Nicolaou KC; Van Meir EG
Clin Cancer Res; 2012 Dec; 18(24):6623-33. PubMed ID: 22923450
[TBL] [Abstract][Full Text] [Related]
2. Menadione and ethacrynic acid inhibit the hypoxia-inducible factor (HIF) pathway by disrupting HIF-1α interaction with p300.
Na YR; Han KC; Park H; Yang EG
Biochem Biophys Res Commun; 2013 May; 434(4):879-84. PubMed ID: 23618863
[TBL] [Abstract][Full Text] [Related]
3. Epidithiodiketopiperazines (ETPs) exhibit in vitro antiangiogenic and in vivo antitumor activity by disrupting the HIF-1α/p300 complex in a preclinical model of prostate cancer.
Reece KM; Richardson ED; Cook KM; Campbell TJ; Pisle ST; Holly AJ; Venzon DJ; Liewehr DJ; Chau CH; Price DK; Figg WD
Mol Cancer; 2014 Apr; 13():91. PubMed ID: 24775564
[TBL] [Abstract][Full Text] [Related]
4. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.
Wang W; Ao L; Rayburn ER; Xu H; Zhang X; Zhang X; Nag SA; Wu X; Wang MH; Wang H; Van Meir EG; Zhang R
PLoS One; 2012; 7(9):e44883. PubMed ID: 23028659
[TBL] [Abstract][Full Text] [Related]
5. RNA interference targeting hypoxia-inducible factor 1α via a novel multifunctional surfactant attenuates glioma growth in an intracranial mouse model.
Gillespie DL; Aguirre MT; Ravichandran S; Leishman LL; Berrondo C; Gamboa JT; Wang L; King R; Wang X; Tan M; Malamas A; Lu ZR; Jensen RL
J Neurosurg; 2015 Feb; 122(2):331-41. PubMed ID: 25423275
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel small-molecule inhibitors of the hypoxia inducible factor pathway.
Mooring SR; Jin H; Devi NS; Jabbar AA; Kaluz S; Liu Y; Van Meir EG; Wang B
J Med Chem; 2011 Dec; 54(24):8471-89. PubMed ID: 22032632
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent.
Mun J; Jabbar AA; Devi NS; Liu Y; Van Meir EG; Goodman MM
Bioorg Med Chem; 2012 Jul; 20(14):4590-7. PubMed ID: 22682301
[TBL] [Abstract][Full Text] [Related]
8. Visualization of hypoxia-inducible factor 1α-p300 interactions in live cells by fluorescence resonance energy transfer.
Kim SY; Lee MJ; Na YR; Kim SY; Yang EG
J Cell Biochem; 2014 Feb; 115(2):271-80. PubMed ID: 23966271
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells.
Duyndam MC; van Berkel MP; Dorsman JC; Rockx DA; Pinedo HM; Boven E
Biochem Pharmacol; 2007 Jul; 74(2):191-201. PubMed ID: 17498666
[TBL] [Abstract][Full Text] [Related]
10. Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor.
Shi Q; Yin S; Kaluz S; Ni N; Devi NS; Mun J; Wang D; Damera K; Chen W; Burroughs S; Mooring SR; Goodman MM; Van Meir EG; Wang B; Snyder JP
ACS Med Chem Lett; 2012 Aug; 3(8):620-5. PubMed ID: 24936238
[TBL] [Abstract][Full Text] [Related]
11. Suppressing the malignant phenotypes of glioma cells by lentiviral delivery of small hairpin RNA targeting hypoxia-inducible factor-1α.
Dong CG; Wu WK; Feng SY; Yu J; Shao JF; He GM
Int J Clin Exp Pathol; 2013; 6(11):2323-32. PubMed ID: 24228093
[TBL] [Abstract][Full Text] [Related]
12. Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents.
Mun J; Jabbar AA; Devi NS; Yin S; Wang Y; Tan C; Culver D; Snyder JP; Van Meir EG; Goodman MM
J Med Chem; 2012 Aug; 55(15):6738-50. PubMed ID: 22746274
[TBL] [Abstract][Full Text] [Related]
13. Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model.
Lo Dico A; Martelli C; Valtorta S; Raccagni I; Diceglie C; Belloli S; Gianelli U; Vaira V; Politi LS; Bosari S; Lucignani G; Moresco RM; Ottobrini L
Eur J Nucl Med Mol Imaging; 2015 Jun; 42(7):1093-105. PubMed ID: 25813354
[TBL] [Abstract][Full Text] [Related]
14. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
[TBL] [Abstract][Full Text] [Related]
15. Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells.
Manohar SM; Padgaonkar AA; Jalota-Badhwar A; Rao SV; Joshi KS
Prostate Cancer Prostatic Dis; 2012 Mar; 15(1):15-27. PubMed ID: 22083267
[TBL] [Abstract][Full Text] [Related]
16. A novel function of novobiocin: disrupting the interaction of HIF 1α and p300/CBP through direct binding to the HIF1α C-terminal activation domain.
Wu D; Zhang R; Zhao R; Chen G; Cai Y; Jin J
PLoS One; 2013; 8(5):e62014. PubMed ID: 23671581
[TBL] [Abstract][Full Text] [Related]
17. Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Sapra P; Kraft P; Pastorino F; Ribatti D; Dumble M; Mehlig M; Wang M; Ponzoni M; Greenberger LM; Horak ID
Angiogenesis; 2011 Sep; 14(3):245-53. PubMed ID: 21452059
[TBL] [Abstract][Full Text] [Related]
18. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Rapisarda A; Hollingshead M; Uranchimeg B; Bonomi CA; Borgel SD; Carter JP; Gehrs B; Raffeld M; Kinders RJ; Parchment R; Anver MR; Shoemaker RH; Melillo G
Mol Cancer Ther; 2009 Jul; 8(7):1867-77. PubMed ID: 19584228
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas.
Jensen RL; Ragel BT; Whang K; Gillespie D
J Neurooncol; 2006 Jul; 78(3):233-47. PubMed ID: 16612574
[TBL] [Abstract][Full Text] [Related]
20. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I.
Ellinghaus P; Heisler I; Unterschemmann K; Haerter M; Beck H; Greschat S; Ehrmann A; Summer H; Flamme I; Oehme F; Thierauch K; Michels M; Hess-Stumpp H; Ziegelbauer K
Cancer Med; 2013 Oct; 2(5):611-24. PubMed ID: 24403227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
